Bicara Therapeutics (NASDAQ:BCAX) COO Ryan Cohlhepp Sells 12,500 Shares

Bicara Therapeutics Inc. (NASDAQ:BCAX) COO Ryan Cohlhepp sold 12,500 shares of the stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $20.29, for a total transaction of $253,625.00. Following the sale, the chief operating officer directly owned 191,641 shares in the company, valued at $3,888,395.89. This trade represents a 6.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ryan Cohlhepp also recently made the following trade(s):

• On Wednesday, April 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The shares were sold at an average price of $23.01, for a total transaction of $287,625.00.
• On Monday, March 16th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The shares were sold at an average price of $19.66, for a total transaction of $245,750.00.
• On Tuesday, March 3rd, Ryan Cohlhepp sold 17,392 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.16, for a total transaction of $315,838.72.

Bicara Therapeutics Stock Down 4.6%

Shares of NASDAQ BCAX traded down $0.94 during trading on Monday, reaching $19.29. 571,810 shares of the company traded hands, compared to its average volume of 531,321. The firm has a 50 day simple moving average of $21.01 and a 200-day simple moving average of $18.20. Bicara Therapeutics Inc. has a 52-week low of $7.80 and a 52-week high of $24.25. The stock has a market capitalization of $1.27 billion, a PE ratio of -6.94 and a beta of -0.57.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.21). As a group, research analysts predict that Bicara Therapeutics Inc. will post -3.37 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on BCAX shares. Wall Street Zen cut shares of Bicara Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday. Wedbush reiterated an “outperform” rating and issued a $30.00 price objective on shares of Bicara Therapeutics in a research note on Tuesday, March 31st. Morgan Stanley increased their price objective on shares of Bicara Therapeutics from $36.00 to $37.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Wednesday, April 8th. Finally, The Goldman Sachs Group increased their price objective on shares of Bicara Therapeutics from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 12th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $30.27.

Institutional Investors Weigh In On Bicara Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Legal & General Group Plc raised its stake in Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after acquiring an additional 1,233 shares during the period. Tower Research Capital LLC TRC raised its position in shares of Bicara Therapeutics by 419.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock valued at $44,000 after buying an additional 3,866 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Bicara Therapeutics during the fourth quarter valued at approximately $45,000. Larson Financial Group LLC raised its position in shares of Bicara Therapeutics by 1,015.5% during the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock valued at $62,000 after buying an additional 3,595 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its position in shares of Bicara Therapeutics by 385.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock valued at $97,000 after buying an additional 4,585 shares during the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.